| Gene symbol | AXL | Synonyms | ARK, AXL3, JTK11, Tyro7, UFO | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | AXL receptor tyrosine kinase | ||||
| Gene symbol | CLDN6 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.3 | dbXrefs | |
| Description | claudin 6 | ||||
| Gene symbol | GPC3 | Synonyms | DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, SGBS, SGBS1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq26.2 | dbXrefs | |
| Description | glypican 3 | ||||
| GTO ID | GTC3064 |
| Trial ID | NCT05410717 |
| Disease | Endometrial Cancer | Testis Refractory Cancer | Ovarian Cancer |
| Altered gene | CLDN6|GPC3|MESO|AXL |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | CLDN6/GPC3/MESO/AXL CAR-NK cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | CLDN6-CAR-NK Cell Therapy for Advanced Solid Tumors |
| Year | 2022 |
| Country | China |
| Company sponsor | Second Affiliated Hospital of Guangzhou Medical University |
| Other ID(s) | ZCARNK-017 |
| Cohort 1 | |||||||
|
|||||||